Idiopathic Juvenile Arthritis (Stills Disease) - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 70 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H2 2014', provides an overview of the Idiopathic Juvenile Arthritis (Still's Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Juvenile Arthritis (Still's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Idiopathic Juvenile Arthritis (Still's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Idiopathic Juvenile Arthritis (Still's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Juvenile Arthritis (Still's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Juvenile Arthritis (Still's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic Juvenile Arthritis (Still's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Idiopathic Juvenile Arthritis (Still's Disease) Overview 7
Therapeutics Development 8
Pipeline Products for Idiopathic Juvenile Arthritis (Still's Disease) - Overview 8
Pipeline Products for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis 9
Idiopathic Juvenile Arthritis (Still's Disease) - Therapeutics under Development by Companies 10
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Idiopathic Juvenile Arthritis (Still's Disease) - Products under Development by Companies 15
Idiopathic Juvenile Arthritis (Still's Disease) - Companies Involved in Therapeutics Development 16
AlphaMab Co., Ltd 16
Biocon Limited 17
Epirus Biopharmaceuticals, Inc. 18
Genor BioPharma Co., Ltd. 19
Mabion SA 20
Pfizer Inc. 21
Sandoz Inc. 22
Swedish Orphan Biovitrum AB 23
UCB S.A. 24
Idiopathic Juvenile Arthritis (Still's Disease) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
abatacept biosimilar - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
adalimumab biosimilar - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
adalimumab biosimilar - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
adalimumab biosimilar - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
adalimumab biosimilar - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
adalimumab biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
adalimumab biosimilar - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
adalimumab biosimilar - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
anakinra (recombinant) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
certolizumab pegol - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
etanercept biosimilar - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
etanercept biosimilar - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tofacitinib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Idiopathic Juvenile Arthritis (Still's Disease) - Recent Pipeline Updates 55
Idiopathic Juvenile Arthritis (Still's Disease) - Dormant Projects 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Tables
Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease), H2 2014 8
Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Comparative Analysis by Unknown Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by AlphaMab Co., Ltd, H2 2014 16
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Biocon Limited, H2 2014 17
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 18
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Genor BioPharma Co., Ltd., H2 2014 19
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Mabion SA, H2 2014 20
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Pfizer Inc., H2 2014 21
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Sandoz Inc., H2 2014 22
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Swedish Orphan Biovitrum AB, H2 2014 23
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by UCB S.A., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Idiopathic Juvenile Arthritis (Still's Disease) Therapeutics - Recent Pipeline Updates, H2 2014 55
Idiopathic Juvenile Arthritis (Still's Disease) - Dormant Projects, H2 2014 68